Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hopefully in the same sense as US optimism after they got their butts kicked in the battle of Kasserine pass in WWII. They replaced poor leadership, reemphasized training and brought in new weapons. Pretty much where we're headed I hope.
Worse than anticipated. This should knock a hole in the share price today.
That wouldn't surprise me. They would want to control the patent. Suppose they offered a 100% premium to the current price to shareholders. 50 cents per share. At that price I would do a little better than break even.
That is what the SC website says
https://www.supremecourt.gov/Search.aspx?FileName=/docket/docketfiles/html/public%5C20-1119.html
Thanks, that's what I thought. Can we claim any benefit yet for that disease?
With respect to question number 4, you list NASH as one of the diseases that vascepa is useful in treating. Have we seen any results in that regard?
Round, like a circle in a spiral
Like a wheel within a wheel.
Never ending or beginning,
On an ever spinning reel…
No big pop in volume so no news. Who knows.
The last two decades? I beg to differ.
Don't worry. The tax will be retroactive. ;)
There are no neurorx shares. It's a private company. Perhaps you meant BRPA?
Could be housing valuations are going up. I know the cost of building houses has skyrocketed .
That's encouraging. However, they publicly admit they haven't submitted the data to the FDA yet. That's not encouraging.
I certainly hope you're right.
The strategy I proposed would work only if this goes to the courts and rlftf runs out of money. Court cases can drag on forever. So, potentially, a judge might not e we get to rule on the case.
Speculation is that GEM will oversee a quick resolution. But what's the reasoning behind this? That GEM owns a billion or more shares of rlftf? Ask yourself what is their actual cost for those shares. It depends on when they bought them and it could be well below 100 million dollars. Would GEM be willing to take that loss if rlftf folds?
Let me give you an analogy. Gardeners typically plant two seeds in every spot and weed out the weaker plant so the stronger will have room to grow. GEM is invested in both neurorx and rlftf. Who's to say they're not the ones behind Neurorx's ploy with the goal of bankrupting rlftf and allowing Neurorx/BRPA to survive and claim the whole market for zyesami. Call it investment gardening.
Bottom line, for those who think GEM will sort this all out, you're right. It just might not end the way you expect.
Disclaimer. This is contrarian speculation on my part and for the record I'm heavily invested in rlftf so I would be more than pleased to discover that I'm dead wrong.
Send him some flowers.
I'm looking for a cat that hates voles. I'll take anything with claws as long as it brings the vole population down, even if the cat stacks them up at my doorstep.
That link doesn't work. Reading yahoo and stocktwits though there is a lot of detailed information regarding trial endpoints.
Appears so. But just think, when the EUA hits in 2 months it will rocket up 1000% to 10 cents!
Correct. Which means there's a need for zyesami. In fact there's a critical need.
Would Gilead sit on favorable NASH results if they had them in hand? First to the market with a viable combo treatment will hit a goldmine.
5,800 Fully Vaccinated Americans Have Contracted COVID-19, 74 Dead: CDC
https://m.theepochtimes.com/5800-fully-vaccinated-americans-have-contracted-covid-19-74-dead-cdc_3777637.html
Read this. It's very encouraging
https://www.reddit.com/r/ReliefTherapeutics/comments/mqa7qi/undervalued_hot_penny_stock_imo/
according to this article a buyout was already priced in and the change of CEO now makes that less certain, hence the drop in price
Vascepa’s CV risk reduction label, alongside the patent setback it suffered in the U.S., has recently made Amarin an attractive buyout target. But as Jefferies’ Yee sees it, a new CEO “may signal no near-term M&A on the table”—and M&A chatter has been driving Amarin’s stock price. Typically speaking, a long-time exec team may see M&A as a way out, while new leadership would want to make a mark by pushing for independent growth.
At the moment, Amarin’s focus remains on promoting the CV label and fending off generics in the U.S. while prepping for the official EU launch, starting with Germany in the third quarter.
U.S. generics are struggling with supply, as a copycat by Hikma has only been able to steal around 10% to 13% market share, and Dr. Reddy’s is delaying its launch. But Yee viewed that as mainly a near-term hiccup, raising doubts about Vascepa’s durability.
https://www.fiercepharma.com/pharma/amarin-hands-ceo-baton-to-eu-commercial-chief-amid-vascepa-launch-as-m-a-looks-less-likely
I read earlier, here I think, that there aren't 800 sales reps. More like 500 plus since Amarin wasn't able to recruit the full complement.
That's what I was implying. Despite the enthusiasm expressed here for all the possible legal remedies,(rule 60 filing, SC hearing, Teva losing their case in the appeals court en banc hearing) I think the odds of any one of those coming to fruition is miniscule.
I do believe the new CEO hire indicates a shift towards a European strategy but realistically that's not better than going generic in the US since the European countries all demand deep discounts from the US market price, some of them more deeply than others.
I would like to see a comparison between last year's script numbers for the first quarter vs this year. My impression is it's flat. And last year was a covid max year. I'm suggesting that the board took a hard look at the numbers and decided the US market is not going to grow the company. If Amarin does decide to go generic in the US and concentrate on Europe they will have narrower margins. Basically the margin generics enjoy which is slim.
As for a buyout, if one does occur, it will be after all the legal issues are settled and if Amarin loses them the buyout will be somewhere under 10 dollars a share.
Is the flip side of your analysis that Amarin is abandoning the US market? Fire the reps and going the generic route? This assumes mgmt has decided all legal remedies will prove fruitless.
Michigan is likely to lock down again. Covid is here to stay.
Ha! This is entertaining.
Theodon- Greek God of Reality and Uncertainty
All here should at least entertain the possibility that the Amarin board conducted a CEO search and had no takers. A remote possibility I think but when I see someone unexpected promoted from within it arouses suspicion in my mind.
The stock is tanking after hours on the news. Tomorrow should be interesting.
Do we even know if the application has been submitted yet? As for the FDA, with vaccines becoming widely available I'm sure they feel less pressure to react and possibly make another mistake like remdesivir.
Unfortunately, I agree.
While zyesami may be effective for use in many respiratory and lung issues it does need the recognition associated with an EUA. Revenue will be needed to further trials for other indications. From my perspective getting the EUA is a binary event.
All stock boards do. It's a law of nature.
It's big. Comes with fries.
I'm thinking Goofy, or maybe Daffy Duck. Sleepy of the seven dwarfs?
USPTO announces special Patents for Humanity COVID-19 category
The United States Patent and Trademark Office (USPTO) today announced that it will be launching a special category of its Patents for Humanity Program for inventions that address the COVID-19 pandemic. This new award category will provide business incentives for patent applicants, holders, and licensees whose inventions track, prevent, diagnose, or treat COVID-19.
“The Commerce Department is committed to supporting the groundbreaking work of the inventors and companies creating the new solutions we need to overcome the pandemic and other global challenges of the future,” said Secretary of Commerce Gina Raimondo. “The Patents for Humanity program stands as a testament to the strength that human ingenuity can bring to solving humanity’s most pressing problems.”
https://www.uspto.gov/about-us/news-updates/uspto-announces-special-patents-humanity-covid-19-category
I hope so. That would be far more advantageous to Amarin. There has been a major shakeup in the court of course so there's no telling where their priorities are right now. Still, even with the court selecting our case for consideration I give it a small chance of being selected for review. Because, well, this is Amarin.